Edition:
United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

26.17EUR
10:45am EST
Change (% chg)

€0.16 (+0.62%)
Prev Close
€26.01
Open
€26.01
Day's High
€26.31
Day's Low
€25.94
Volume
308,471
Avg. Vol
714,107
52-wk High
€28.07
52-wk Low
€21.50

Select another date:

Mon, Oct 29 2018

BRIEF-Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease

* SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER'S DISEASE (AD) PATIENTS

Healthcare firm Grifols S.A. wins U.S. antitrust nod to buy Biotest US Corp

WASHINGTON Global healthcare company, Grifols S.A. , which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

Healthcare firm Grifols S.A. wins US antitrust nod to buy Biotest US Corp

WASHINGTON, Aug 1 Global healthcare company, Grifols S.A., which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

BRIEF-Grifols Expands Its Blood Typing Solutions Portfolio In US With Antisera Reagents

* GRIFOLS EXPANDS ITS BLOOD TYPING SOLUTIONS PORTFOLIO IN THE UNITED STATES WITH ANTISERA REAGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: